Pentapeptide-18 and delivery route: what the topical data actually supports

Pentapeptide-18, sold under the name Leuphasyl, has never been formulated or tested as an injectable. Short answer: the topical-versus-injectable question for pentapeptide-18 has a one-sided answer, because injectable delivery doesn't currently exist for this peptide, and the topical evidence that does exist is thinner than most product pages let on.

I get asked about this pairing a lot, usually from people who've used BPC-157 or TB-500 by injection and assume every peptide eventually graduates to a needle if it's any good. That's not how this one works, and it's worth walking through why.

Why pentapeptide-18 stays topical

Pentapeptide-18 mimics enkephalin, a molecule your body already uses to bind opioid receptors on pre-synaptic neurons. When it binds those receptors, calcium influx into the neuron drops, which cuts down on catecholamine release and, downstream, muscle contraction. That's the whole pitch: less signal reaching the muscle fibers under expression lines, so the skin over them creases less over time.

This mechanism was mapped and marketed as a topical cosmetic ingredient from the start. It sits in the same "topical Botox" family as Argireline and Syn-Ake, all of which were designed as topical treatments applied to the skin over the muscles they target. Nobody has run the safety, absorption, or dosing work you'd need before you could responsibly inject a peptide, and as far as I can find, nobody has tried. The compound was built, studied, and sold as a topical the entire time.

What the topical evidence actually shows

Here's where I want to slow down, because this is the part product listings gloss over. The strongest data point people cite for pentapeptide-18 is a 2024 cohort study using a retinol and oligopeptide nanocarrier formulation, which reported reduced sebum and improved facial wrinkles with good tolerability. That sounds like a win, and the tolerability finding is genuinely useful information about skin response. But the peptide wasn't tested alone. It was combined with retinol, a well-established wrinkle-reducing ingredient in its own right, inside a carrier system designed to boost penetration. You can't isolate how much of that result came from pentapeptide-18 versus the retinol doing what retinol already does.

The rest of the supporting literature is lab-bench and computational work rather than human trials. One paper models the peptide's receptor-binding behavior in silico, and another examines related oligopeptide structures in vitro. Both are useful for understanding mechanism and plausibility. Neither tells you what happens on a person's forehead over twelve weeks using pentapeptide-18 by itself.

I try to stay evidence-based with peptides. My read on this data set is that pentapeptide-18 is the best-documented member of its relaxer family on paper, with four studies behind it, while still lacking a single clean human trial that isolates its own effect. That's a reason to treat the marketing claims with a little more skepticism than the study count alone would suggest.

Could injectable delivery even help here?

This is the part worth thinking through mechanistically, because the reasoning doesn't automatically favor an injectable route the way it might for a systemic peptide like a GLP-1 or a repair peptide such as BPC-157. Pentapeptide-18's job is local: it needs to reach the pre-synaptic neurons feeding specific facial muscles, in low concentrations, applied repeatedly over the surface where those muscles sit close to the skin. An injectable version would need to solve targeted delivery to those same superficial neuromuscular junctions, and at that point you're closer to reinventing botulinum toxin's delivery model than improving on a topical relaxer peptide. Systemic injection would spread the peptide well beyond the muscles you're trying to affect, with no established pharmacokinetic or safety data to tell you what that dose curve even looks like in a person.

Topical is the delivery route the mechanism actually calls for, and nobody has built a case, in the literature or otherwise, for injecting it instead.

The real-world protocol

Since there's no injectable form, the only protocol worth discussing is topical. Commercial serums typically stack pentapeptide-18 with Argireline and SNAP-8, on the reasoning that three relaxer peptides hitting different points in the same contraction pathway will outperform one. I haven't seen a standalone concentration figure published for pentapeptide-18 by itself, which is common for cosmetic peptide blends where manufacturers treat the formula as proprietary. Most people applying these serums do so once or twice daily to clean, dry skin over the target area, consistent with how the retinol-nanocarrier study delivered it.

Now the part my lawyer makes me say, and he's right: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

If you're weighing pentapeptide-18 against a different topical relaxer for your own routine, I'd read through how it compares mechanistically to its most common stack partner before you commit to a formula, since the two don't do identical jobs even though they're marketed together constantly.

Pentapeptide-18 is a reasonable, low-risk addition to a topical relaxer stack if you go in with realistic expectations about the evidence, and it simply doesn't have an injectable counterpart to weigh it against. That's the state of the research right now, and until someone runs a standalone human trial, that's unlikely to change.